Cost benefit analysis of monitoring serum vancomycin concentrations in a teaching hospital

Journal of Pharmacy Practice

Volumn 10, Issue 2, 1997, Pages 122-126

  Oparaoji, Edward C ^a   Siram, Suryanarayana ^b   Anosike, Rofina ^a   Pippalla, Rao S ^a   Mezghebe, Haile M ^b  

^a HOWARD UNIVERSITY   (United States)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DRUG MONITORING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; PATIENT MONITORING; STAPHYLOCOCCUS INFECTION;

EID: 0030914336     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/089719009701000208     Document Type: Article

References (15)

1. Draugalis J, Bootman J, Larson L, et al. Current Concept: Pharmacoeconomics. Kalamazoo, Michigan: Upjohn; 1989
2. Sanchez L, Lee J. Use and misuse of pharmacoeconomic terms: A definition primer. Top Hospital Pharm. Management. 1994; 13(4):11-42
3. Wilhem MP. Vancomycin. Mayo Clin. Prac. 1991; 66:1165-1170
4. Cantu G., Yamanaka-Yuen N, Liestaman P. Serum vancomycin concentrations: Reappraisal of their clinical value. Clinical Infectious Diseases. 1994; 18:533-543
5. Freeman D, Quintihani R, Nightingale C. Vancomycin therapeutic drug monitoring: Is it necessary? Annal Pharmacother. 1993; 27:594-598
6. Vance-Bryan K, Rotschafer J, Gilland Set al. A comparative assessment of vancomycin associated nephrotoxicity in young versus the elderly hospitalized patients. J. Antimicrobial Chem. 1994;33:811-821
7. Goldstein E, Batholomew W, Parr T et al. Monitoring vancomycin levels: When to start? JAMA. 1993; 270:1496-1497
8. Kirby WMM. Treatment of staphylococcal septicemia with vancomycin. NEJM. 1960; 263: 49-55
9. Sorrell TC, Collingnon PJ: A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob Chemother 16:235-241, 1985
10. Fekety R: Vancomycin. Med Clin North Am. 66:175-181, January 1982
11. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982; 136:362-364
12. Ena J, Dick RW, Jones RR et al. The epidemiology of intravenous vancomycin usage in University hospital. A 10 year study, JAMA. 1993; 269:598-602
13. Vancomycin Product Information. Lederle Parentherals, Inc. Canolina Puerto Rico. May 1991
14. Matzke GR, McGory RW, Haltenson CE, et al. Pharmacokinetics: Principles of therapeutic drug monitoring, 3rd ed. Spokane, WA: Applied Therapeutics. 1992; 15-1-15-31
15. DiPiro JT, Edmiston CE, Bohnen JMA. Pharmacodynamics of antimicrobial therapy in surgery. Am J Surg. 1996; 171:615-622.